GlassScriptPhysician profile
Wendy A Graefe
NPI 1851301626
$2,790.31
in general payments reported to CMS, 2019-2025
20 companies · $384 in 2025
The $384 reported for 2025 was more than what 93% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $521 · 2023: $928 · 2024: $663 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.22 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $620.33 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $482.87 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $339.05 | 2021-2022 | |
| Amgen INC. | $257.55 | 2021-2025 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $233.69 | 2022-2025 | |
| Abbvie INC. | $220.20 | 2021-2023 | |
| Shield Therapeutics INC | $112.15 | 2023-2024 | Accrufer |
| Organon LLC | $91.33 | 2022-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $72.80 | 2021-2023 | |
| Pfizer INC. | $59.77 | 2021-2024 | |
| Exeltis, USA INC. | $54.89 | 2021-2024 | Nuvessa, Slynd |
| Biogen, INC. | $45.48 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $36.73 | 2022 | |
| Hologic Sales and Service, LLC | $36.43 | 2024-2025 | Aptima, Acessa Provu System |
| Channel Medsystems, INC. | $26.66 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $24.67 | 2022 | |
| Daiichi Sankyo INC. | $21.74 | 2023 | Injectafer |
| Scynexis, INC. | $20.63 | 2022 | |
| Millicent US INC | $16.97 | 2025 | Femring, Intrarosa |
| Evofem Biosciences, INC. | $16.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Graefe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.